SCHEMBL3105398

SCHEMBL3105398

N#Cc1ccc(NCCNc2nc(-c3ccccc3C(F)(F)F)nc3c2CCCC3)nc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP1 O94782 8/20 0.47
WDR48 Q8TAF3 8/20 0.47
GSK3B P49841 1/20 0.42
CYP1A2 P05177 6/20 0.38
CYP3A4 P08684 5/20 0.38
CYP2D6 P10635 3/20 0.38
TSHR P16473 1/20 0.38
CLK4 Q9HAZ1 3/20 0.38
CYP2C19 P33261 3/20 0.38
USP2 O75604 2/20 0.38
TRPV1 Q8NER1 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HSD17B10 Q99714 1/20 0.37
GLA P06280 2/20 0.37
CYP2C9 P11712 1/20 0.37
METAP1 P53582 1/20 0.36
AGTR2 P50052 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3102992 0.84 USP1 (0.43) USP1WDR48GSK3BCYP1A2CYP3A4
SCHEMBL3105236 0.81 GSK3B (0.51) USP1WDR48GSK3BCYP1A2CYP3A4
SCHEMBL3251693 0.81 USP1 (0.68) USP1WDR48CYP1A2CYP3A4CYP2D6
SCHEMBL13300279 0.79 GSK3B (0.50) GSK3BCLK4
SCHEMBL6647396 0.78 USP1 (0.46) USP1WDR48GSK3BCYP1A2CYP3A4
SCHEMBL3112200 0.78 USP1 (0.46) USP1WDR48GSK3BCYP1A2CYP3A4
SCHEMBL6646698 0.77 USP1 (0.46) USP1WDR48GSK3BCYP1A2CYP3A4
SCHEMBL3109466 0.73 CYP1A2 (0.46) USP1WDR48GSK3BCYP1A2CYP3A4
SCHEMBL3098618 0.69 CYP1A2 (0.56) USP1WDR48GSK3BCYP1A2CYP3A4
SCHEMBL13300221 0.69 CYP1A2 (0.57) USP1WDR48GSK3BCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2198867-A1 Pyrimidine-based compounds useful as GSK-3 inhibitors Vertex Pharmaceuticals, Inc. (US) 2010-06-23 EP disclosed
EP-2198867-A1 Pyrimidine-based compounds useful as GSK-3 inhibitors Vertex Pharmaceuticals, Inc. (US) 2010-06-23 EP disclosed
EP-1474147-B1 PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS VERTEX PHARMA (US) 2010-05-05 EP disclosed
EP-1474147-A1 PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2004-11-10 EP disclosed
US-20030199526-A1 Pyrimidine-based compounds useful as GSK-3 inhibitors VERTEX PHARMACEUTICALS, INCORPORATED 2003-10-23 US disclosed
WO-2003049739-A1 PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS VERTEX PHARMACEUTICALS, INC. (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199526-A1 Pyrimidine-based compounds useful as GSK-3 inhibitors GSK3B, GSK3A, GSKIP USP1 4041/4885WDR48 1964/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.